Supplementary Table 4. Pain Freedom by Timepoint (mITT Population): ACHIEVE I and ACHIEVE II

	ACHIEVE I							ACHIEVE II						
	Placebo	Ubrogepant 50 mg			Ubrogepant 100 mg			Placebo	Ubrogepant 25 mg			Ubrogepant 50 mg		
Hours Post Dose	n/N1	n/N1	Odds Ratio (95% CI)	P-value	n/N1	Odds Ratio (95% CI)	P-value		n/N1	Odds Ratio (95% CI)	P-value	n/N1	Odds Ratio (95% CI)	P-value
0.5	3/432	7/398	2.43 (0.71, 10.2)	0.1527	3/419	0.95 (0.20, 4.55)	0.9449	7/429	2/399	0.3 (0.06, 1.46)	0.1349	7/434	0.88 (0.30, 2.55)	0.8145
1	22/449	17/408	0.86 (0.45, 1.65)	0.6483	12/437	0.53 (0.26, 1.10)	0.0881	24/443	23/415	1.01 (0.56, 1.82)	0.9746	20/451	0.77 (0.42, 1.42)	0.3998
1.5	41/450	50/416	1.39 (0.89, 2.15)	0.1449	56/444	1.44 (0.93, 2.21)	0.0997	44/449	45/423	1.07 (0.69, 1.67)	0.7504	50/456	1.08 (0.70, 1.67)	0.7181
2	54/456	81/422	1.83 (1.25, 2.66)	0.0017	95/448	2.04 (1.41, 2.95)	0.0001	65/456	90/435	1.56 (1.09, 2.22)	0.0143	101/464	1.62 (1.14, 2.29)	0.0065
3	93/456	160/422	2.45 (1.81, 3.31)	<0.0001	164/448	2.28 (1.69, 3.08)	<0.0001	104/456	140/435	1.60 (1.18, 2.16)	0.0024	157/464	1.69 (1.26, 2.27)	0.0005
4	129/456	198/422	2.330 (1.73, 3.05)	<0.0001	216/448	2.40 (1.81, 3.16)	<0.0001	139/456	201/435	1.96 (1.48, 2.59)	<0.0001	209/464	1.83 (1.39, 2.41)	<0.0001
6	190/456	247/422	2.04 (1.55, 2.68)	<0.0001	260/448	1.98 (1.51, 2.59)	<0.0001	187/456	257/435	2.07 (1.58, 2.72)	<0.0001	268/464	1.96 (1.49, 2.52)	<0.0001
8	235/456	287/422	2.07 (1.57, 2.74)	<0.0001	295/448	1.86 (1.42, 2.45)	<0.0001	219/456	279/435	1.93 (1.47, 2.53)	<0.0001	311/464	2.17 (1.66, 2.85)	<0.0001
24	319/456	327/422	1.55 (1.14, 2.12)	0.0052	352/448	1.60 (1.18, 2.17)	0.0027	306/456	332/435	1.56 (1.16, 2.11)	0.0033	350/464	1.47 (1.10, 1.97)	0.0090
48	361/456	345/422	1.19 (0.85, 1.67)	0.3057	370/448	1.25 (0.90, 1.75)	0.1876	349/456	339/435	1.07 (0.78, 1.46)	0.6845	383/464	1.43 (1.03, 1.98)	0.0315

N1 = Number of patients with non-missing postdose pain severity assessment at or prior to the timepoint in the modified intent-to-treat population.
Missing data was handled using last observation carried forward.
Includes data from all participants, including those who took rescue medication or an optional second dose of trial treatment.

Odds ratio (95% CI) and p-value are based on logistic regression with treatment group, historical triptan response, use of medication for migraine prevention, and baseline headache severity as explanatory variables.
Percentages calculated as 100 x (n/N1)